Claims for Patent: 10,457,970

Summary for Patent: 10,457,970

Title:	Expression of modified glycoproteins and glycopeptides
Abstract:	The present invention provides recombinant cells that contain a modification causing altered expression or function of at least one mannosyl transferase enzyme. As a result of the modification the cells produce a glycoprotein or glycopeptide that has an N-linked glycan profile that is simplified or humanized. The glycoprotein or glycopeptide can have at least 25% fewer high mannose structures on than the glycoprotein or glycopeptide produced by a cell that does not have the modification. In some embodiments the modification is a deletion, knock out, or disruption of a gene encoding a mannosyl transferase, which can be in an Alg3 gene. Therefore, the proteins produced avoid many of the problems associated with the therapeutic use of glycoproteins from species having foreign or plant-like patterns of glycosylation. The invention also provides compositions of the glycoproteins or glycopeptides and methods of making them.
Inventor(s):	Caiazza; Nicky C. (Rancho Santa Fe, CA)
Assignee:	Conagen Inc. (Bedford, MA)
Application Number:	15/799,785
Patent Claims:	1. A recombinant cell of the Class Labyrinthulomycetes comprising a genetic modification of a gene that encodes a mannosyl transferase, and further comprising a recombinant nucleic acid encoding a functional glycoprotein or glycopeptide, wherein the cell produces a heterologous glycoprotein or glycopeptide having an N-linked glycan profile that has at least 25% fewer high mannose structures than the N-linked glycan profile from a reference cell that does not comprise the genetic modification in the gene that encodes the mannosyl transferase. 2. The cell of claim 1 wherein the genetic modification is selected from a deletion, an insertion, a replacement, or a disruption. 3. The cell of claim 1 wherein the genetic modification is a deletion, and the mannosyl transferase is an alpha-1,3-mannosyl transferase. 4. The cell of claim 3 wherein the mannosyl transferase is of the class EC 2.4.1.258. 5. The cell of claim 1 wherein the glycoprotein is an antibody. 6. The cell of claim 5 wherein the heterologous glycoprotein is selected from the group consisting of: trastuzumab, eculizumab, natalizumab, cetuximab, omalizumab, usteinumab, panitumumab, and adalimumab, or a functional fragment of any of them. 7. The cell of claim 3 wherein the heterologous glycoprotein or glycopeptide has an N-linked glycan profile having at least 50% fewer high mannose N-linked glycans than the N-linked glycan profile from a Labyrinthulomycetes cell that does not comprise the mannosyl transferase deletion. 8. The cell of claim 1 wherein the glycoprotein or glycopeptide has an N-linked glycan profile having less than 50% high mannose structures. 9. The Labyrinthulomycetes cell of claim 3 selected from the group consisting of: Aurantiochytrium, Schizochytrium, and Thraustochytrium, further wherein the genetic modification is a deletion, and the mannosyl transferase is alg3. 10. The cell of claim 9 which is an Aurantiochytrium sp. 11. The cell of claim 1 wherein the glycoprotein or glycopeptide comprises at least 50% fewer high mannose structures. 12. The cell of claim 1 wherein the glycoprotein or glycopeptide comprises at least 25% more paucimannose structures versus the cell that does not comprise the mannosyl transferase genetic modification. 13. The cell of claim 1 wherein more than 50% of the N-linked glycans comprise a paucimannose structure. 14. The cell of claim 13 wherein the paucimannose structure comprises a Man3 structure. 15. A method of producing a glycoprotein or glycopeptide that comprises a simplified N-glycan profile comprising: a) performing a genetic modification in a gene that encodes a mannosyl transferase in a host cell of the Class Labyrinthulomycetes; b) cultivating the host cell; c) harvesting a glycoprotein or glycopeptide from the cell that has a simplified N-linked glycan profile wherein at least 50% of the N-linked glycans comprise a Man3 and/or Man4 glycan structure. 16. The method of claim 15 wherein the mannosyl transferase is an alpha-1,3-mannosyl transferase. 17. The method of claim 16 wherein the mannosyl transferase is of the class EC 2.4.1.258. 18. The method of claim 16 wherein the genetic modification is a deletion, and the glycoprotein is an antibody. 19. The cell of claim 18 wherein the glycoprotein antibody is selected from the group consisting of: trastuzumab, eculizumab, natalizumab, cetuximab, omalizumab, usteinumab, panitumumab, and adalimumab, or a functional fragment of any of them. 20. The method of claim 15 wherein the glycoprotein or glycopeptide comprises at least 50% fewer N-linked glycans versus a host cell that does not comprise the mannosyl transferase deletion. 21. The method of claim 15 wherein the N-linked glycan profile comprises less than 50% high mannose structures. 22. The method of claim 15 wherein the Labyrinthulomycete cell is selected from the group consisting of: Aurantiochytrium, Schizochytrium, and Thraustochytrium, further wherein the genetic modification is a deletion and the mannosyl transferase is alg3. 23. The method of claim 22 wherein the Labyrinthulomycete is an Aurantiochytrium. 24. The method of claim 15 wherein the glycoprotein or glycopeptide comprises at least 50% fewer high mannose structures. 25. The method of claim 15 wherein the glycoprotein or glycopeptide comprises at least 25% more paucimannose structures versus the cell that does not comprise the mannosyl transferase deletion. 26. The method of claim 15 wherein more than 50% of the N-linked glycans comprise a man3 glycan structure. 27. The method of claim 15 wherein the N-glycan structure comprises at least 70% Man3 and/or Man4 structures. 28. The recombinant cell of claim 3 wherein the gene that encodes a mannosyl transferase is alg3. 29. The method of claim 15 wherein the genetic modification is a deletion, and the gene that encodes a mannosyl transferase is alg3.

Details for Patent 10,457,970

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2036-11-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2036-11-01
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003		2036-11-01
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018		2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2036-11-01